
5 questions on Sarepta, the FDA and a Duchenne gene therapy crisis
One month ago, a 51-year-old man treated in a clinical trial with an experimental gene therapy became dangerously sick. The developer of that treatment, Sarepta Therapeutics, informed the Food and Drug Administration his case could be life-threatening. …